Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance

Amphastar Pharmaceuticals IncTrade
Vanguard Dividend Appreciation Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Vanguard Dividend Appreciation Index Fund ETF trades at $245.68. The key difference: Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

AMPHVIG
Market Cap
$863.95M
Sector
Health
52-Week High
$30.81$245.79
52-Week Low
$16.87$208.67
Enterprise Value
$1.26B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Vanguard Dividend Appreciation Index Fund ETF

VIG trades at $245.23, up 0.35% over 24 hours, with a bullish technical signal driven by moving averages and a dividend of $1.00 scheduled for June 2026. The ETF focuses on dividend growth, holding stocks like Broadcom, which has surged 710% over five years (24/7 Wall Street, 2026-07-22).

The outlook is positive for long-term investors seeking steady income, supported by a 20-year dividend growth streak, but risks include high RSI levels indicating overbought conditions and potential market volatility from AI and interest rate uncertainties (Zacks Investment Research, 2026-07-30).

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Vanguard Dividend Appreciation Index Fund ETF

The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VIG